Patients with chronic spontaneous urticaria experienced substantial reductions in hives and itch with briquilimab through 16 ...
News Medical on MSN2d
Granzyme K+ CD8+ T-cells identified as key drivers of recurrent airway inflammationResearchers identify a pathogenic subset of CD8+ memory T-cells that promote airway tissue inflammation and recurrent ...
Blueprint Medicines' Ayvakit shows strong revenue growth, projected to reach over $2 billion in peak sales. Read my analysis ...
News Medical on MSN3d
Antihistamine shows promise for treating rare genetic liver diseaseA common antihistamine may offer hope for patients with a rare genetic disease that can lead to severe liver damage and ...
Rapid onset of deep and durable clinical responses observed across multiple dosing cohorts with a favorable safety profileMean change in UAS7 ...
Analyst Silvan Tuerkcan of JMP Securities reiterated a Buy rating on Allakos (ALLK – Research Report), with a price target of $3.00.Stay Ahead ...
The company's focus on mast cell-mediated diseases positions it in a potentially lucrative market. CSU alone affects over three million patients in the United States, with only one FDA-approved ...
Jasper Therapeutics, Inc. (NASDAQ:JSPR), with a market capitalization of $105.23 million, is a clinical-stage biotechnology company focused on developing innovative treatments for mast cell-mediated ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback